News Sentiment

CLDX sentiment intelligence

Celldex Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 39.11 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

84/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+1.9% over one week, +25.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Celldex Therapeutics, Inc. Announces Retirement of Sam Martin from Senior Vice President, Effective on or About March 31, 2027

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 84/100 classification
One-week reaction 1.9% Price digesting
Trend fit Trend active 25.1% over four weeks
Fair value 31.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 43
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 22
Market source 10
TradingView 6
GlobeNewswire 5
simplywall.st 4
marketscreener.com 3
MT Newswires 2
Sahm 2

Event Lens

What the news is about

Classified themes
Market update 40
Earnings 14
Deals and strategy 3
Regulatory and legal 2
Balance sheet 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
Investing.com Canada Direct company coverage

Celldex CFO Sam Martin to retire in March 2027 By Investing.com

Sam Martin, Celldex Therapeutics' Senior Vice President and Chief Financial Officer, announced his retirement effective March 2027. Martin has been with the company's finance team since 2009 and served as CFO since 2017, overseeing a period of strong financial health. Celldex, wh

Tone
Positive 65/100
Event
Market update
Published
15 Jul 2026 20:12
Source
Investing.com Canada
Stock Titan Direct company coverage

Celldex Starts CFO Search as Martin Plans 2027 Retirement

Celldex (NASDAQ:CLDX) announced that its Senior Vice President and Chief Financial Officer, Sam Martin, plans to retire in March 2027. Martin, who has served as CFO since 2017 and has been with Celldex since 2009, will remain in his role during the search for a successor to ensur

Tone
Positive 60/100
Event
Market update
Published
15 Jul 2026 20:12
Source
Stock Titan
GlobeNewswire Direct company coverage

Celldex Announces Planned Transition of Chief Financial Officer

Celldex announced that Sam Martin, Senior Vice President and Chief Financial Officer, plans to retire in 2027. Mr. Martin, who has been with Celldex since 2009 and CFO since 2017, will remain in his role until March 2027 to ensure a smooth transition while the company searches fo

Tone
Positive 59/100
Event
Market update
Published
15 Jul 2026 20:12
Source
GlobeNewswire
Stock Titan Direct company coverage

Celldex Therapeutics (NASDAQ: CLDX) CFO to retire around March 2027

Celldex Therapeutics announced that its Senior Vice President and Chief Financial Officer, Sam Martin, plans to retire around March 31, 2027. Martin, who has been with the company since 2009 and CFO since 2017, will remain in his role until his successor is appointed to ensure a

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:12
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX

The article focuses on the "Price to sales forward" financial metric for Celldex Therapeutics, Inc. (NASDAQ: CLDX) as presented on TradingView. It provides a brief financial overview without specific numeric values but mentions the company's stock information and market status. T

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 13:13
Source
TradingView
TradingView Direct company coverage

Price to book forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX

This article provides a brief mention of the "Price to book forward" for Celldex Therapeutics, Inc. (NASDAQ: CLDX) as listed on TradingView. It appears to be a stub or a data point within a larger financial platform, offering no further analytical content. The primary focus is me

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 02:12
Source
TradingView
Sahm Direct company coverage

Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed?

Celldex Therapeutics (CLDX) was recently added to several Russell growth indexes, increasing its visibility to institutional investors. While this inclusion and recent share price strength help with liquidity, the core investment risks - clinical trial outcomes for its barzolvoli

Tone
Positive 67/100
Event
Balance sheet
Published
06 Jul 2026 14:41
Source
Sahm
TradingView Direct company coverage

Price to earnings forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX

This page from TradingView provides financial information for Celldex Therapeutics, Inc. (NASDAQ: CLDX), specifically focusing on its forward Price to Earnings (P/E) ratio. The article indicates that the market is closed and no trades have occurred for CLDX, and lists various dat

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 11:10
Source
TradingView
Stock Titan Direct company coverage

CLDX SEC Filings - Celldex Therapeutics Inc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Celldex Therapeutics (CLDX) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It details recent filings such as insider stock option grants, beneficial ownership statements, and

Tone
Negative 41/100
Event
Market update
Published
01 Jul 2026 12:40
Source
Stock Titan
Stock Titan Direct company coverage

Celldex (CLDX) SVP granted 95,000 options at $34.09 strike

Celldex Therapeutics, Inc. reported that Margo Heath-Chiozzi, SVP of Regulatory Affairs, was granted 95,000 incentive stock options at an exercise price of $34.09 per share. These options, issued under the company’s 2021 Omnibus Equity Incentive Plan, will vest 25% on June 25, 20

Tone
Neutral 50/100
Event
Regulatory and legal
Published
30 Jun 2026 15:12
Source
Stock Titan
Stock Titan Direct company coverage

Celldex (NASDAQ: CLDX) grants SVP & counsel 93,000 stock options

Celldex Therapeutics (NASDAQ: CLDX) granted 93,000 incentive stock options to its SVP & General Counsel, Freddy A. Jimenez, with an exercise price of $34.09 per share. These options, issued under the company's 2021 Omnibus Equity Incentive Plan, will vest 25% on June 25, 2027, wi

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 10:39
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Celldex Therapeutics, Inc. Insider Trading Activity

Celldex Therapeutics, Inc. (CLDX) reported insider trading activity where director Denice Torres was granted 26,000 non-qualified stock options. These options allow her to buy common stock at an exercise price of $34.09 per share, granted on June 25, 2026, and expiring on June 25

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:51
Source
Stock Titan
Stock Titan Direct company coverage

Celldex Therapeutics (CLDX) CFO awarded 93,000 stock options grant

Celldex Therapeutics' SVP and CFO, Martin Samuel Bates, was granted 93,000 incentive stock options at an exercise price of $34.09 per share under the company's 2021 Omnibus Equity Incentive Plan. The options begin vesting 25% on June 25, 2027, with the remainder vesting quarterly

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

Celldex (CLDX) SVP awarded 95,000-share stock option grant at $34.09

Celldex Therapeutics, Inc.'s SVP of Corporate Affairs & Administration, Sarah Cavanaugh, was granted incentive stock options for 95,000 shares at an exercise price of $34.09 per share. The options will vest 25% on June 25, 2027, with the remainder vesting quarterly over the subse

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

Celldex Therapeutics (CLDX) grants 20,000 stock options to senior VP

Celldex Therapeutics, Inc. (CLDX) has granted its Senior Vice President and Chief Business Officer, Ronald Pepin, an incentive stock option for 20,000 shares of common stock. The options have an exercise price of $34.09 per share, with 25% vesting on June 25, 2027, and the remain

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

Celldex (CLDX) CMO Diane Young receives 57,000 stock options grant

Celldex Therapeutics, Inc. reported that its SVP and Chief Medical Officer, Diane C. Young, was granted 57,000 Incentive Stock Options. These options, with an exercise price of $34.09 per share, are part of her compensation and will vest over several years, with 25% vesting on Ju

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

Celldex Therapeutics (CLDX) director receives grant of 26,000 stock options

Celldex Therapeutics director Herbert J. Conrad was granted 26,000 non-qualified stock options with an exercise price of $34.09 per share, expiring on June 25, 2036. This grant, under the company's 2021 Omnibus Equity Incentive Plan, increases his total option holdings to 26,000

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 19:41
Source
Stock Titan
Stock Titan Direct company coverage

Celldex (CLDX) director receives 26,000 stock options under 2021 incentive plan

Celldex Therapeutics, Inc. director Harry Jr Penner was granted 26,000 non-qualified stock options under the company’s 2021 Omnibus Equity Incentive Plan. These options, with an exercise price of $34.09 per share, expire on June 25, 2036, and are compensation-related rather than

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 19:41
Source
Stock Titan
www.marketscreener.com Direct company coverage

Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 2500 Growth Benchmark

Celldex Therapeutics, Inc. (NasdaqCM: CLDX) has been added to the Russell 2500 Growth Benchmark, a significant inclusion that indicates its growing presence in the market. The company is a clinical-stage biotechnology firm focused on developing therapeutics for severe inflammator

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 19:41
Source
www.marketscreener.com
Investing.com Direct company coverage

Celldex Therapeutics stock hits 52-week high at 35.8 USD

Celldex Therapeutics (CLDX) stock reached a 52-week high, closing at $35.80 and trading at $35.92, reflecting a 74.25% increase over the past year. This surge is supported by positive clinical trial data for its CDX-622 antibody and barzolvolimab, which has led to maintained or u

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 09:36
Source
Investing.com